Proof-of-concept study of VK2809 for treatment of glycogen storage disease type Ia (GSD Ia)

Next Previous
Trial Profile

Proof-of-concept study of VK2809 for treatment of glycogen storage disease type Ia (GSD Ia)

Planning
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs VK 2809 (Primary)
  • Indications Glycogen storage disease type I
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 17 Aug 2017 New trial record
    • 09 Aug 2017 According to a Viking Therapeutics media release, the company plans to file an IND application for VK2809 for the treatment of patients with GSD Ia and initiate a human proof-of-concept study in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top